Previous 10 | Next 10 |
AlloVir press release (NASDAQ:ALVR): FY GAAP EPS of -$2.74 misses by $0.10. As of December 31, 2021, company had cash, cash equivalents and marketable securities of $248.1 million, compared with cash, cash equivalents and marketable securities of $356.3 million as of December 31, 2020. For ...
Three ongoing Phase 3 registrational studies of posoleucel expected in 2022, targeting treatment and prevention indications with no approved therapies Expanded enrollment in Phase 2 proof-of-concept study of posoleucel for the preemptive treatment of BK viremia in kidney trans...
AlloVir manufactures T cells ex vivo, off-the-shelf, for curing viral infections in HSCT patients. Its technology has similarities and differences with a number of other companies, discussed here. ALVR presents an interesting approach to an unmet medical need. For further de...
Treatment of AdV infection is posoleucel’s second potential indication to receive RMAT designation Phase 3 registrational study of posoleucel for AdV treatment is now open for enrollment Proof-of-concept study of ALVR106 for the treatment of multiple respiratory...
AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 4:30 p.m. ET. An audio-only we...
AlloVir (NASDAQ:ALVR) announces Augustin Melian, MD, Chief Medical Officer, has decided to leave the company at the end of this year. Although officially leaving the company, Dr. Melian has agreed to work with AlloVir in an advisory capacity to ensure a smooth transition. Richa...
AlloVir (Nasdaq: ALVR) today announced that Augustin Melian, MD, Chief Medical Officer, has decided to leave the company at the end of this year. Although officially leaving the company, Dr. Melian has agreed to work with AlloVir in an advisory capacity to ensure a smooth transition. ...
Of the 23 high-risk allogeneic hematopoietic cell transplant patients in this analysis, no end-organ viral disease was observed Of the 13 patients who completed through the Week 14 primary endpoint, 11 remained free of clinically significant infection Strength of these...
AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced today that the company will participate in the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference. A pre-recorded fireside chat will be available from Monday, November 22 to Thursday, D...
AlloVir (NASDAQ:ALVR): Q3 GAAP EPS of -$0.72. Cash, cash equivalents, and marketable securities of $275.8M Press Release For further details see: AlloVir reports Q3 results
News, Short Squeeze, Breakout and More Instantly...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...